LGALS3 and neoplasm: These studies provide the rationale for inhibiting LAG3/GAL-3, in combination with immunotherapy including a cancer vaccine, to overcome the immune suppressive tumor microenvironment, enhance anti-tumor-specific immune responses, and improve patient outcome in MM.